Patents by Inventor Photon Rao

Photon Rao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9115066
    Abstract: Provided herein are trisubstituted methyl alcohols, preferably pH indicators that are substituted with optionally substituted aryl and or optionally substituted heteroaryl groups, and optionally include one or more polymerizable substituents.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: August 25, 2015
    Assignee: Indicator Systems International, Inc.
    Inventors: Gerald F. Swiss, Photon Rao, Ram W. Sabnis
  • Publication number: 20130261317
    Abstract: This invention relates generally to methods for preparing certain bile acids from non-mammalian sourced starting materials as well as to synthetic bile acids and compositions comprising such acids wherein the acids are characterized by a different C14 population than naturally occurring bile acids as well as being free from any mammalian pathogens. This invention is also directed to the synthesis of intermediates useful in the synthesis of such bile acids. Accordingly, the C ring of the steroidal scaffold is oxidized to provide a synthetic route and intermediates to DCA. This invention also provides synthetic methods for preparing deoxycholic acid or a salt thereof starting from aromatic steroids such as estrogen, equilenin, and derivatives thereof. This invention is also directed to intermediates such as 12-oxo or delta-9,11-ene steroids as well as novel processes for their preparation.
    Type: Application
    Filed: September 19, 2011
    Publication date: October 3, 2013
    Applicant: KYTHERA BIOPHARMACEUTICALS, INC.
    Inventors: Robert M. Moriarty, Photon Rao
  • Patent number: 8299088
    Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: October 30, 2012
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Publication number: 20090312276
    Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: June 12, 2009
    Publication date: December 17, 2009
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Patent number: 7550496
    Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: June 23, 2009
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Publication number: 20080214576
    Abstract: Compositions and methods for treating cancer and other hyperproliferatice disease conditions with topoisomerase inhibitors and their prodrugs are disclosed.
    Type: Application
    Filed: November 27, 2005
    Publication date: September 4, 2008
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Photon Rao
  • Publication number: 20070043057
    Abstract: Lonidamine analogs are useful in the treatment and prevention of cancer, benign prostatic hyperplasia, macular degeneration and prostatic intraepithelial neoplasia, or for use as an antispermatigenic agent.
    Type: Application
    Filed: February 1, 2006
    Publication date: February 22, 2007
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Publication number: 20070015771
    Abstract: Lonidamine analogs are useful in the treatment and prevention of cancer, benign prostatic hyperplasia, macular degeneration and prostatic intraepithelial neoplasia, or for use as an antispermatigenic agent.
    Type: Application
    Filed: February 8, 2006
    Publication date: January 18, 2007
    Applicant: Threshold pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Publication number: 20060258656
    Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: March 29, 2004
    Publication date: November 16, 2006
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Publication number: 20060142207
    Abstract: Methods and compositions are provided for the treatment of cancer that take advantage of the increased uptake of glucose-anti-neoplastic agent conjugates in cancer cells relative to normal cells.
    Type: Application
    Filed: December 1, 2005
    Publication date: June 29, 2006
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: George Tidmarsh, Mark Matteuccii, Photon Rao
  • Patent number: 7001888
    Abstract: Methods and compositions are provided for the treatment of cancer that take advantage of the increased uptake of glucose-anti-neoplastic agent conjugates in cancer cells relative to normal cells.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: February 21, 2006
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: George Tidmarsh, Mark Matteucci, Photon Rao
  • Publication number: 20040029815
    Abstract: Methods and compositions are provided for the treatment of cancer that take advantage of the increased uptake of glucose-anti-neoplastic agent conjugates in cancer cells relative to normal cells.
    Type: Application
    Filed: March 28, 2003
    Publication date: February 12, 2004
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: George Tidmarsh, Mark Matteucci, Photon Rao